Document:

Exclusivity Agreement

 Exhibit 10.26 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

January 20, 2012 
 Mitsubishi Chemical
Corporation 
 14-1, Shiba 4-chome, Minato-ku 
 Tokyo 108-0014 
 Japan 

 

	Attn:	Mr. Shigeru Handa 

 General
Manager Sustainable Resources 
 Petrochemicals R&D Division 
 Dear Mr. Handa: 
 This letter agreement (the “Letter Agreement”)
between Mitsubishi Chemical Corporation (“MCC”) and Genomatica, Inc. (“Genomatica”) is intended to be legally binding on both parties. In consideration of the mutual covenants contained herein and
other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
  

	1.	The parties agree to negotiate in good faith the terms of definitive agreements (the “Definitive Agreements”) for the joint commercial operation
in Asia (as defined below) and the Middle East (as defined below) of 1,4-butanediol (“BDO”) manufacturing using the process and technologies developed by Genomatica (the “Transaction”) and agree to use
all reasonable efforts to execute the Definitive Agreements by June 30, 2012 or such other date as otherwise agreed between the parties, the execution of which shall be subject to (i) satisfactory result of feasibility study and/or due
diligence to be conducted by each party, (ii) the approval of the respective management committee of each party, if any, and (iii) the approval of the respective Boards of Directors of each party. The Definitive Agreements together with
its ancillary agreements will contain reasonable provisions of representations, warranties, indemnities, deadlock solution, exit procedures, license conditions, and other provisions as the parties deem necessary and appropriate.

	2.	Until June 30, 2012, (the “Negotiation Period”), Genomatica shall negotiate exclusively with MCC, and shall not engage in negotiations with
or enter into an agreement with any other party that manufactures, sells and/or markets BDO or [...***...] in Asia and the Middle East, regarding a collaboration, joint venture or similar transaction to produce BDO using the process and
technologies developed by Genomatica in Asia and the Middle East (the “Limited Exclusivity Agreement”). During the Negotiation Period, MCC shall not enter into discussions, negotiations, collaboration, joint development or
similar transaction to produce Bio-BDO in Asia and the Middle East. As used herein, “Asia” means any and all of the countries of Cambodia, China, Hong Kong, Indonesia, Japan, Laos, Malaysia, Maldives, Mongolia, Nepal, North
Korea, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand and Vietnam. As used herein, “Middle East” means any and all of the countries of Bahrain, Iran, Iraq, Jordan, Kuwait, Lebanon, Oman, Palestine, Qatar, Saudi Arabia,
Syria, United Arab Emirates, and Yemen. Within five (5) business days after the execution of this Letter Agreement, MCC shall make a payment to Genomatica of three and a half million US Dollars (US$3,500,000) for the Limited Exclusivity
Agreement (the “Exclusivity Fees”), all or any portion of which will be refunded by Genomatica to MCC pursuant to Section 3 below. 

 

	3.	a) Genomatica agrees to repay to MCC an amount of two million five hundred thousand US Dollars (US$2,500,000) according to the invoice to be issued by MCC in the case
where, as a result of or in the course of, due diligence investigations, feasibility study and negotiation of the Definitive Agreements on the Transaction, any of the following events occurs by [...***...] or such other date as otherwise
agreed between the parties: 

  

	 	(i)	Genomatica and MCC fail to agree that the internal rate of return for the Transaction is more than [...***...] based on a mutually developed financial model;

  

	 	(ii)	Any item which, either of Genomatica or MCC deems, gives material adverse effects on the Transaction is found as a result of the due diligence to be conducted by
Genomatica or MCC, as the case may be; 

  

	 	(iii)	Any force majeure event (including, but not limited to, the world- wide economy recession), which is beyond reasonable control of Genomatica or MCC, as the case may be,
occurs and such event prevents the affected 

 ***Confidential Treatment Requested 

  
 Page 2

	 	
party from entering into the Transaction without acceptance of unreasonable terms and conditions; or 

  

	 	(iv)	Genomatica and MCC fail to agree to the terms of the Definitive Agreements, which shall be reasonable and satisfactory to both parties. 

b) In case Genomatica decides not to move forward on the Transaction for any cause or reason other than those set forth in subsection a)
above, Genomatica shall repay to MCC, and MCC shall be entitled to the repayment from Genomatica of, the entire amount of three million five hundred thousand US Dollars (US$3,500,000) according to the invoice to be issued by MCC. 

c) In case MCC decides not to move forward on the Transaction for any cause or reason other than those set forth in subsection a) above,
MCC shall not be entitled to any repayment from Genomatica and Genomatica shall not have any obligation to make any repayment of the Exclusivity Fees. 
 d) In the event that Genomatica and MCC successfully execute the Definitive Agreements, Genomatica agrees to repay to MCC an amount of one million seven hundred fifty thousand US Dollars (US$1,750,000)
according to the invoice to be issued by MCC. 
  

	4.	As promptly as practicable after the execution of this Letter Agreement, each of the parties will conduct, as it deems necessary and appropriate for the purpose of
implementing the Transaction, due diligence investigations and feasibility study on the Transaction during the term of this Letter Agreement, which is to be completed by [...***...] or such other date as otherwise agreed between the parties.

 Each of the parties will make its information available, and give reasonable access to its facilities and
personnel, to the other party and/or its representatives and advisors for purposes of such due diligence, and will cooperate with each other to meet all reasonable requests of the other in connection therewith. 

 

	5.	The term of this Letter Agreement shall commence on the date of execution of this Letter Agreement by both parties and continue until the earliest to occur of
(a) the execution of the Definitive Agreements, (b) June 30, 2012 or (c) the date that either party terminates this Letter pursuant to the following sentence. Either party may terminate this Letter Agreement for material breach
of this Letter Agreement by the other party upon 30 days’ written notice specifying the nature of the breach, if such breach has not been cured within such 30 day period. Termination of this Letter 

***Confidential Treatment Requested 

  
 Page 3

	 	
Agreement shall not relieve the parties of any obligation accruing prior to such termination including, without limitation, any obligation of MCC to make any payment set forth in this Letter
Agreement. 

  

	6.	Except as required by applicable law (including applicable securities regulations), neither party hereto shall make any public disclosure concerning the existence of
this Letter Agreement, its contents or the status of the negotiations between Genomatica and MCC with respect to the transactions contemplated hereby without obtaining the prior written consent of the other party. The parties acknowledge and agree
that the information exchanged by the parties in connection with this Letter Agreement and the transactions contemplated hereby is subject to the nondisclosure agreement between the Genomatica and MCC dated August 12, 2010, and agree that the
term of such nondisclosure agreement is hereby extended until termination of this Letter Agreement. 

  

	7.	This Letter Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, USA, without regard to its choice of law
provisions. Neither party may assign this Letter Agreement without the prior written consent of the other party; provided, however, that Genomatica may assign this Letter Agreement without MCC’s consent in connection with the transfer or sale
of all or substantially all of the business of Genomatica relating to BDO, whether by merger, sale of stock, sale of assets or otherwise. Any attempted assignment of this Letter Agreement not in compliance with this Section 7 shall be null and
void. This Letter Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 

  
 Page 4

 If this Letter Agreement is acceptable, please have a copy executed by MCC’s duly authorized
representative and return it to the undersigned no later than December 15, 2011. 
  

			
	Very truly yours,
	
	Genomatica, Inc.
		
	By:	 	 /s/ William Baum

		 	William Baum
		 	Executive Chairman of the Board and
		 	Chief Business Development Officer

  

			
	Agreed:
	
	Mitsubishi Chemical Corporation
		
	Signature:	 	 /s/ Shigeru Handa

		
	Name:	 	 Shigeru Handa

		
	Title:	 	 General Manager

		
	Date:	 	 January 23, 2012

  
 Page 5Fourth Amendment to Lease, dated November 4, 2011

 Exhibit 10.19 
 FOURTH AMENDMENT TO LEASE 
 This Fourth Amendment to
Lease (this “Fourth Amendment”), made as of the 4th day of November, 2011, by and between ARE-MA REGION NO. 28, LLC, a Delaware limited liability company (“Landlord”) and ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation
(“Tenant”). 
 W I T N E S S E T H:

 WHEREAS, Landlord and Tenant are parties to a Lease dated as of September 26, 2003 (the “Original
Lease”), as amended by a First Amendment to Lease dated March 16, 2006 between Landlord (as successor to Three Hundred Third Street LLC), and Tenant (as successor to Alnylam U.S., Inc., a Delaware corporation that is a subsidiary of
Tenant and was formerly known as Alnylam Pharmaceuticals, Inc. (the “Original Tenant”), pursuant to an Assignment of Lease dated February 28, 2006 between Original Tenant and Tenant), by a Second Amendment to Lease between
Landlord and Tenant dated June 26, 2009 and by a Third Amendment to Lease between Landlord and Tenant (“Third Amendment”) dated May 11, 2010 (as so amended, the “Lease”); and 

WHEREAS, pursuant to the Lease, Landlord leases to Tenant certain premises within the building known and numbered as 300 Third
Street, Cambridge, Massachusetts (the “Building”), which premises include but are not limited to space on the first, second, third and fourth floors of the Building and are more particularly described in the Lease; and 

WHEREAS, pursuant to that certain Sublease between Tenant and sanofi-aventis U.S. Inc., a Delaware corporation
(“Sanofi”) dated August 3, 2010, as amended by a First Amendment to Sublease (the “Sanofi First Amendment”) dated November 4, 2011 (as such Sublease is so amended, the “Sanofi Sublease”),
with respect to which Landlord, Tenant and Sanofi have executed that certain Consent to Sublease dated August 3, 2010 and Consent to First Amendment to Sublease dated November 4, 2011 (the “Consent to Sanofi First
Amendment”), respectively, Tenant currently subleases to Sanofi certain space on Level 01, the acid neutralization room on Level P-2 and the chemical storage room on Level P-1, all as more particularly described in the Sanofi Sublease
(collectively, the “Subleased Premises”); and 
 WHEREAS, Landlord and Tenant desire to amend the Lease
with respect to Excess Income (as defined in the Lease) so that the provisions set forth in Section 5 of the Third Amendment will no longer apply and the terms and conditions of the Original Lease pertaining to Excess Income will apply to all
assignment and subletting, including without limitation, to the Excess Income from the Sanofi Sublease, as set forth in this Fourth Amendment; and 
 WHEREAS, Landlord and Tenant have agreed to amend the Lease to, among other things, change the allocation of Excess Income with respect to assignment and subletting, including without limitation
the Sanofi Sublease, all as more particularly provided below. 

 NOW, THEREFORE, in consideration of the foregoing and other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby covenant and agree as follows: 
 1. Defined Terms. All capitalized terms used and not otherwise defined herein shall have the respective meanings ascribed to them in the Lease. In the event of any inconsistency between the
Lease and this Fourth Amendment, the provisions of this Fourth Amendment shall control, and all other provisions of the Lease shall remain in full force and effect. 
 2. Excess Income. The Lease is hereby amended so that, from and after January 1, 2012, the second grammatical paragraph of Section 5 of the Third Amendment (which begins with the
words “Tenant and Landlord agree that 100% ...”) shall no longer apply to Excess Income, and the terms and conditions of the Original Lease pertaining to Excess Income, including without limitation the terms and conditions of
Section 16(D) of the Original Lease, shall apply to all assignment and subletting, including without limitation the Excess Income from the Sanofi Sublease. 
 (a) Tenant is receiving from Sanofi, as partial consideration for the execution and delivery of the Sanofi First Amendment, a one-time payment of One Million Five Hundred Thousand Dollars ($1,500,000)
(the “One-Time Payment”). Notwithstanding anything to the contrary contained in the Third Amendment or this Fourth Amendment, upon receipt by Tenant of such One-Time Payment, Tenant shall promptly pay Landlord in immediately
available funds the amount of Six Hundred Thousand Dollars ($600,000) as Additional Rent under the Lease. 
 (b) The provisions
of Section 5 of the Third Amendment and Section 16(D) of the Original Lease shall govern for their respective applicable time periods with respect to Excess Income from rent and other sums payable by Sanofi pursuant to the Sanofi Sublease,
except as follows: 
 (i) The One-Time Payment shall not be included in the calculation of Excess Income, and
payment to Landlord of the portion of the One-Time Payment described in Section 2(a) above shall be in lieu of payment of any Excess Income with respect to the One-Time Payment; and 

(ii) If Sanofi terminates the Sublease early in accordance with Section 4(b) of the Sanofi First Amendment such that
the effective date of such termination is December 31, 2013, then Landlord and Tenant agree that, with respect to the payment by Sanofi to Tenant of One-Million-One-Hundred-Twenty-Thousand-Seven-Hundred-Sixty-One Dollars and Thirty Cents
($1,120,761.30) (the “Termination Fee”), the Excess Income under Section 16(D) of the Lease will continue to be calculated and paid by Tenant for each of the months of January through June 2014 as if the portion of the
Termination Fee equal to six months of Base Rent for each of such months (i.e., One-Hundred-Fifty-Eight-Thousand-Seven-Hundred-Thirty-Two-Dollars ($158,732) per month) were Base Rent paid by Sanofi under the Sanofi First Amendment for the months

  
 2 

 
of January through June 2014, notwithstanding such early termination by Sanofi (to the extent that the Termination Fee includes the repayment of unamortized brokerage fees and other transaction
costs, such repaid brokerage fees and transaction costs shall not be included as Tenant’s Transfer Expenses under Section 16(D) of the Lease); and 
 (iii) If, and only if, following such termination in accordance with Section 4(b) of the First Amendment to Sublease, the Subleased Premises under the Sanofi Sublease (the “Vacant
Space”) is vacant or not used or occupied by Tenant or any party exercising rights by, through or under Tenant for any month or part of a month after June 30, 2014, then in the calculation of Excess Income with respect to a future
sublease of the Vacant Space, the portion of Base Rent paid by Tenant under the Lease with respect to the Vacant Space for each month in the period of such vacancy or nonuse (each, a “Vacancy Month”) will be deemed to be added and
applied to the amount of Tenant’s Transfer Expenses in clause (b) in the calculation of Excess Income for each month of the term of such future sublease as set forth in Section 16(D) of the Lease until each such Vacancy Month has been
so applied, or if earlier, until the expiration or earlier termination of such future sublease. No early termination rights granted by Tenant to Sanofi in the Sanofi Sublease or the exercise thereof by Sanofi shall affect the Term of the Lease or
Tenant’s monthly rental obligations pursuant to the Lease. 
 3. Ratification of Lease; Effect of Fourth
Amendment. The Lease, as amended by this Fourth Amendment, is hereby ratified and confirmed, and each and every provision, covenant, condition, obligation, right and power contained in and under, or existing in connection with, the Lease, as
amended by this Fourth Amendment, shall continue in full force and effect from and after the date hereof and throughout the Term. This Fourth Amendment is not intended to, and shall not be construed to, effect a novation, and, except as expressly
provided in this Fourth Amendment, the Lease has not been modified, amended, canceled, terminated, surrendered, superseded or otherwise rendered of no force and effect. Tenant acknowledges and agrees that the Lease, as amended by this Fourth
Amendment, is enforceable against Tenant in accordance with its terms. The Lease and this Fourth Amendment shall be construed together as a single instrument. This Fourth Amendment is the entire agreement between the parties with respect to the
subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. This Fourth Amendment may be amended only by an agreement in writing signed by the parties hereto. 

4. No Defaults, Counterclaims or Rights of Offset; Release of Landlord. Tenant hereby warrants and represents that, to its
knowledge, as of the date of the execution of this Fourth Amendment by Tenant, there are no defaults under the Lease in respect of Landlord’s performance thereunder and there exist no defenses, counterclaims or rights of offset with respect
thereto. Tenant, for itself, its officers, directors, members, shareholders and their respective legal representatives, successors and assigns, does hereby absolutely and irrevocably waive, remise, release and forever discharge Landlord,

  
 3 

 
its successors, assigns, partners, employees, affiliates, attorneys and agents, of and from any and all manner of action and actions, cause and causes of actions, suits, debts, dues, sums of
money, accounts, reckoning, bonds, bills, specialties, covenants, contracts, controversies, agreements, promises, variances, trespasses, damages, judgments, extents, executions, claims and demands whatsoever, in law or in equity, for items or
matters that Tenant could have been aware of or known about, through and including the date of execution and delivery of this Fourth Amendment in connection with or relating to the Lease or the transactions contemplated hereby. Nothing contained in
this paragraph shall be construed to release Tenant from its obligations under the Lease throughout the Term of the Lease (including the Extended Term, if any). 
 5. Brokers. Landlord and Tenant represent and warrant to each other that neither has dealt with any broker, finder or agent in procuring this Fourth Amendment except for Richards Barry
Joyce & Partners (the “Broker”). Tenant and Landlord represent and warrant to each other that, except with respect to the Broker, who represented Tenant, no broker, agent, commission salesperson, or other person has represented it
in the negotiations for and procurement of this Fourth Amendment and that with respect to this Fourth Amendment no commissions, fees, or compensation of any kind are due and payable in connection herewith to any broker, agent, commission
salesperson, or other person. Tenant and Landlord agree to indemnify and hold harmless each other, its agents, members, partners, representatives, officers, affiliates, shareholders, employees, successors and assigns from and against any and all
loss, liabilities, claims, suits, or judgments (including, without limitation, reasonable attorneys’ fees and court costs incurred in connection with any such claims, suits, or judgments, or in connection with the enforcement of this indemnity)
for any fees, commissions, or compensation of any kind which arise out of or are in any way connected with any claimed agency relationship not referenced in this paragraph. 
 6. Successors and Assigns. This Fourth Amendment shall bind and inure to the benefit of the parties hereto and their respective permitted successors and assigns. 

7. Counterparts. This Fourth Amendment may be executed in a number of identical counterparts, each of which for all
purposes shall be deemed to be an original, and all of which shall collectively constitute but one agreement, fully binding upon, and enforceable against the parties hereto. 
 [remainder of page intentionally left blank] 

  
 4 

 IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment as of the
day and year first written above. 
  

			
	TENANT:
	
	ALNYLAM PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Michael Mason

	Name:	 	      Michael Mason

	Title:	 	      VP of Finance

  

							
	LANDLORD:
	
	ARE-MA REGION NO. 28, LLC,
	a Delaware limited liability company
		
	By:	 	Alexandria Real Estate Equities, L.P.,
		 	a Delaware limited liability company, its member
			
		 	By:	 	ARE-QRS Corp., a Maryland corporation,
		 		 	its general partner
				
		 		 	By:	 	 /s/ Eric S. Johnson

		 		 	Name:	 	      Eric S. Johnson

		 		 	Title:	 	      Vice President

		 		 		 	     Real Estate Legal Affairs

  
 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]